McDermott Advises Ascensia Diabetes Care Management on Implementation of Management Participation Program - McDermott Will & Emery

McDermott Advises Ascensia Diabetes Care Management on Implementation of Management Participation Program

Overview


Munich (November 21, 2016) – McDermott Will & Emery has advised the international management team of Ascensia Diabetes Care with regard to the implementation of a management participation program. Ascensia Diabetes Care operates the diabetes care business that was disposed of by Bayer in June 2015 for approximately EUR 1 billion to Panasonic Healthcare Holdings, Co., Ltd. Panasonic Healthcare Holdings is backed by the Panasonic Corporation and in an amount of 80 percent by funds sponsored by leading global investment firm Kohlberg Kravis Roberts & Co (KKR). The international set-up of management, the type of instruments offered and the Japanese context added particular complexity to the matter. Advice was rendered in cooperation with Anderson Mori Tomotsune (Tokyo).

Advisor Management

McDermott Will & Emery (Munich): Dr. Nikolaus von Jacobs, Dr. Germar Enders (both lead, Corporate, Munich), Christoph Coenen (Finance, Düsseldorf), Matthias Weingut (Corporate, Munich), Eric Orsic (Corporate, Chicago)

Anderson Mori Tomotsune (Tokyo)

Advisor KKR

Simpson Thacher & Bartlett

Nishimura & Asahi (Tokyo)